References

Scientific Publications (peer-reviewed)

Accepted for publication: Berit Hackenberg; Matthias Büttner; Michelle Schöndorf; Sebastian Strieth; Wendelin Schramm; Christoph Matthias; Haralampos Gouveris. Quality of Life Assessment for Tonsillar Infections and Their Treatment. Medicina (ISSN 1648-9144) on 22 April 2022

Diedrich L, Brinkmann M, Dreier M, Schramm W, Krauth C. Additional offer of sigmoidoscopy in colorectal cancer screening in Germany: rationale and protocol of the decision-analytic modelling approach in the SIGMO study. BMJ Open. 2022 Jan 6;12(1):e050698. doi: 10.1136/bmjopen-2021-050698. PMID: 34992106; PMCID: PMC8739067.

Tew M, Willis M, Asseburg C, Bennett H, Brennan A, Feenstra T, Gahn J, Gray A, Heathcote L, Herman WH, Isaman D, Kuo S, Lamotte M, Leal J, McEwan P, Nilsson A, Palmer AJ, Patel R, Pollard D, Ramos M, Sailer F, Schramm W, Shao H, Shi L, Si L, Smolen HJ, Thomas C, Tran-Duy A, Yang C, Ye W, Yu X, Zhang P, Clarke P. Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Med Decis Making. 2021 Dec 15:272989X211065479. doi: 10.1177/0272989X211065479. Epub ahead of print. PMID: 34911405.

Larribère L, Gordejeva J, Kuhnhenn L, Kurscheidt M, Pobiruchin M, Vladimirova D, Martin M, Roser M, Schramm W, Martens UM, Eigenbrod T. Assessment of SARS-CoV-2 Infection among Healthcare Workers of a German COVID-19 Treatment Center. Int J Environ Res Public Health. 2021 Jul 1;18(13):7057. doi: 10.3390/ijerph18137057. PMID: 34281000

Si, L., et al. (2020). "Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge." Value Health 23(9): 1163-1170. (Schramm W), DOI: 10.1016/j.jval.2020.04.1832, PMID: 32940234

Pobiruchin M, Zowalla R, Kurscheidt M, Schramm W. PrositNG – A Machine Learning Supported Disease Model Generation Software. Studies in Health Technology and Informatics 272:151-154. DOI: 10.3233/shti200516

Schramm W, Sailer F, Pobiruchin M, Müller A, Weissman J. The Cost-Effectiveness of the PDM-ProValue Diabetes Management Program in Germany. EASD 2019, 16.-20. September 2019, Barcelona. P820.
Sailer F, Pobiruchin M, Müller A, Weissmann J, Schramm W. Makrovaskuläre Ereignisse, Lebensqualität und Mortalität im PDM-ProValue Studienprogramm – eine vergleichende Langzeitsimulation. Diabetologie und Stoffwechsel 2019; 14(S 01): S13. DOI: 10.1055/s-0039-1688141

Schramm W. Digital Diabetes Self-Management: A Trilateral Serial. Journal of Diabetes Science and Technology(2018), DOI 10.1177/1932296818761973

Heinemann L, Daenschel W, Daenschel I, Messinger D, Schramm W, Vesper I, Weissmann J, Kulzer B: Integrated personalized diabetes management (iPDM) in patients with insulin-treated T2DM: results of the PDM-ProValue study program. Poster Presentation at the Congress of the International Diabetes Federation in Abu Dhabi 2017 DOI: 10.1177/1932296815617487

Sailer F, Hunter R, Schramm W (2017): Development of a chlamydia infection model for evaluating costs and outcomes of health interventions. In: GMS Medizinische Informatik, Biometrie und Epidemiologie 13 (1). DOI: 10.3205/mibe000173
Schramm W, Rickmann J, Sailer F. Healthy, Sick, Dead – An Education Blueprint to State Transition Disease Modelling. Studies in Health Technology and Informatics Health 2017, PMID: 28679929
Seitz P, Fendrich L, Hempe H, Rickmann J, Christophidis B, Lankes S, Reimchen H, Westers M, Baumann B, Laha A, Suleder J, Sailer F, Schramm W (2017): Validierung des PROSIT CHD Type 2 Diabetes Herzinfarktmodells. In: Diabetologie und Stoffwechsel 12 (S 01), S1-S84. DOI: 10.1055/s-0037-1601719

Pobiruchin M, Bochum S, Martens UM, Kieser M, Schramm W. A method for using real world data in breast cancer modeling. J Biomed Inform. 2016 Feb 8. pii: S1532-0464(16)00019-8. doi: 10.1016/j.jbi.2016.01.017.

Kulzer, B.; Daenschel, W.; Daenschel, I.; Siegel, E. G.; Schramm, W.; Parkin C.G.; Messinger, D.; Weissmann, J.; Djuric, Z.; Mueller, A.; Vesper, I.; Heinemann, L.: Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes. In: Journal of Diabetes Science and Technology (2015). DOI: 10.1177/1932296815617487

Sailer F, Pobiruchin M, Bochum S, Martens UM, Schramm W. Prediction of 5-Year Survival with Data Mining Algorithms. Studies in Health Technology and Informatics. 2015; 213:75-78. DOI: 10.3233/978-1-61499-538-8-75; PMID: 26152957

Pobiruchin M, Kieser M, Schramm W. Leveraging Markov models to compute prevalence estimates for a regional breast cancer registry. Stud Health Technol Inform. 2013;190:237-9.

Willert T, Walker J, Schramm W. [Regional analysis of drug treatment prevalence and medication of diabetes mellitus in Germany]. Dtsch Med Wochenschr. 2012 Nov;137(46):2363-8. doi: 10.1055/s-0032-1327273. Epub 2012 Nov 6. German.

Schramm W. Self-Monitoring of Blood Glucose: One STeP Forward? Journal of Diabetes Science and Technology, July 2012, Volume 6, Issue 4: pages 978–982.

Schramm W, Schöll M, Hess F. Therapy of Chronic Pain in Peripheral Diabetic Neuropathy. IQWIG pilot assessment report on the relation of benefits to costs. IQWIG Institute. (1) 1-71. 23. May 2009.

Pobiruchin M, Schramm W. [Does DMP type 2 diabetes mellitus lead to better values of HbA1c and blood pressure? An analysis regarding to published quality reports] MMW Fortschr Med 2008 Apr 10.:16-21.

Martin S, Schramm W, et al. Epidemiology of Complications and Total Treatment Costs from Diagnosis of Type 2 Diabetes in Germany (ROSSO 4). Experimental Endocrinology and Diabetes. 2007 Sep;115(8):495-501.

Neeser K, Szucs T, Bulliard JL, Bachmann G, Schramm W. Cost-effectiveness analysis of a quality-controlled mammography screening program from the swiss statutory health-care perspective: quantitative assessment of the most influential factors. Value Health. 2007 Jan-Feb;10(1):42-53.

Poster award of the Swiss Society for Radiology, June 2006.

Schramm W, Haake D, Brandt A. Die Wirtschaftlichkeit von Tiotropium bei chronisch obstruktiver Lungenerkrankung. Schweizerische Rundschau für Medizin 2005-11-16;94(46): 1803 - 1810.

Schramm W, Schoffski O, Gortz A, Liebl A. [Disease modelling in diabetes mellitus] Dtsch Med Wochenschr. 2004 Oct 22;129(43):2305-10. Review. German.

K. Neeser, U. Siebert, G. Lübben, W. Schramm: Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective. Pharmacoeconomics. 2004;22(5):321-41.

Schramm W et al., the WHO St. Vincent Declaration Nephropathy Working Group: when is the optimal time for first referral of diabetes patients to a nephrologist? Diabet Med. 2003 Aug;20(8):689-90.

Schramm W. Abbildungen und Simulationen von Krankheiten in mathematischen Modellen und ökonomische Beurteilung medizinischer Outcomes. In ArzneimForsch/DrugRes, 2002, 52, 4, p. 309-351.

Piehlmeier W, Renner R, Schramm W, Schneider A, Konig A, Gottsmann M, Hardenberg R, Von Hubbenet JE, Landgraf R.: PROSIT--a quality management system for diabetic patients with nephropathy in Germany. Diabetes Nutr Metab. 2001 Apr;14(2):110-4.

Piehlmeier W, Renner R, Schramm W, Kimmerling T, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.: Screening of diabetic patients for microalbuminuria in primary care--The PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes. 1999;107(4):244-51.

Piehlmeier W, Renner R, Kimmerling T, Schramm W, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.: Evaluation of the Micral-Test S, a qualitative immunologic patient self-test for microalbuminuria: the PROSIT project. Proteinuria Screening and Intervention. Diabet Med. 1998 Oct;15(10):883-5.

General Publications

W. Schramm, M. Pobiruchin. Die PROSIT Disease Modelling Community Open Source Erkrankungsmodelle für die Kosten-Nutzen Bewertung. Horizonte (37) 2011, p. 38-40.

W. Schramm: from „educated guess“ to evidence-based decision. Management & Krankenhaus. Kolumne „Querdenker“, 03/2003.

U. Schweppe, W. Schramm. Das Richtige mit dem Richtigen tun - Risikostratifizierung als Methode des Managements in der Medizin. Managed Care 7 2002 p. 34-36.

Paolo Brunetti, Carlo Lucioni, Wendelin Schramm: Terapia combinata con Pioglitazone (Actos) nel diabete di tipo 2 in Italia: valutazione farmacoeconomica, Pharmacoeconomic Issues in Type II Diabetes (Italian edition), ADIS international, ISBN: 88 88371 12 5.

W. Schramm. Rechtsmedizin pur, Lehrbuch in Karteikarten für Studenten, Börm-Bruckmeier Verlag, ISBN 3-929785-02-1.

Online Care Card Diabetes (developed by IMIB) www.diabetes-online.ch. The "Online-Gesundheits-Pass Diabetes" is an online version of the "CareCard Diabetes", a common standard document for diabetes care in Switzerland

Swiss Seminar Public Health System, Edition TrendCare, Switzerland: Chapter “Key Figures of the Swiss Health Care System”, ISBN : 3-9521639-0-2

Swiss Seminar Public Health System, Edition TrendCare, Switzerland: Chapter “Disease Management for Diabetes mellitus” ISBN : 3-9521639-0-2

Landgraf R, Renner R, Schramm W. Diabetische Nephropathie in Deutschland – das PROSIT Projekt. Apotheker Journal 1997;19(7):12-15.

Logo des Audits familiengerechte Hochschule. Die HHN ist seit 2005 zertifiziert.
Logo der weltoffenen Hochschulen gegen Fremdenfeindlichkeit
Logo der Charta der Vielfalt mit Stempel unterzeichnet
Logo der Hochschulföderation Süd-West (HfSW)